Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (12)
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Boos, J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Boos, J.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 14:1-5, 2003
© 2003 European Society for Medical Oncology

Editorial

Off label use—label off use?

J. Boos

University Children’s Hospital Muenster, Department of Paediatric Haematology and Oncology, Münster, Germany (E-mail: boosj@uni-muenster.de)

The first 150 words of the full text of this article appear below.

During the last century broad medical progress arose from the development of treatment strategies from natural remedies and the industrial production of drugs. Where there used to be a direct relationship between the natural healer or physician recommending an individualised treatment, the pharmacist preparing a custom-made prescription and the single patient, there is now a drugs market with the pharmaceutical industry on the supplier side, the patient as consumer and physicians who ideally prescribe drugs based on evidence and according to pertinent guidelines. The reproducibility and quality of diagnostic procedures as well as the drug supply have increased and the general benefit for society and individual patients is obvious. Cancer patients have benefited significantly from this process and the overall cure rate of >70% in paediatric malignancies would not have been achieved without cytostatic drugs developed and provided by the pharmaceutical industry.

This process, however, was paralleled by a number . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ANN INTERN MEDHome page
M. R. Gillick
Controlling Off-Label Medication Use
Ann Intern Med, March 3, 2009; 150(5): 344 - 347.
[Abstract] [Full Text] [PDF]

Home page
 Ann OncolHome page
P. G. Casali and On behalf of the Executive Committee of ESMO
The off-label use of drugs in oncology: a position paper by the European Society for Medical Oncology (ESMO)
Ann. Onc., December 1, 2007; 18(12): 1923 - 1925.
[Full Text] [PDF]

Home page
 Ann OncolHome page
M. Coleman
Not credible: a subversion of science by the pharmaceutical industry. Commentary on A global comparison regarding patient access to cancer drugs (Ann Oncol 2007; 18 Suppl 3: pp 1 75)
Ann. Onc., September 1, 2007; 18(9): 1433 - 1435.
[Full Text] [PDF]